JPWO2022090158A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022090158A5
JPWO2022090158A5 JP2023525044A JP2023525044A JPWO2022090158A5 JP WO2022090158 A5 JPWO2022090158 A5 JP WO2022090158A5 JP 2023525044 A JP2023525044 A JP 2023525044A JP 2023525044 A JP2023525044 A JP 2023525044A JP WO2022090158 A5 JPWO2022090158 A5 JP WO2022090158A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
composition
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546504A5 (https=
JP2023546504A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/079543 external-priority patent/WO2022090158A1/en
Publication of JP2023546504A publication Critical patent/JP2023546504A/ja
Publication of JPWO2022090158A5 publication Critical patent/JPWO2022090158A5/ja
Publication of JP2023546504A5 publication Critical patent/JP2023546504A5/ja
Pending legal-status Critical Current

Links

JP2023525044A 2020-10-26 2021-10-25 ヒト対象におけるタウを減少させる方法 Pending JP2023546504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105,804 2020-10-26
PCT/EP2021/079543 WO2022090158A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Publications (3)

Publication Number Publication Date
JP2023546504A JP2023546504A (ja) 2023-11-02
JPWO2022090158A5 true JPWO2022090158A5 (https=) 2024-09-17
JP2023546504A5 JP2023546504A5 (https=) 2024-09-17

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525044A Pending JP2023546504A (ja) 2020-10-26 2021-10-25 ヒト対象におけるタウを減少させる方法

Country Status (11)

Country Link
US (1) US20220127345A1 (https=)
EP (1) EP4232155A1 (https=)
JP (1) JP2023546504A (https=)
KR (1) KR20230093499A (https=)
CN (1) CN116916955A (https=)
AU (1) AU2021367878A1 (https=)
CA (1) CA3199806A1 (https=)
IL (1) IL302386A (https=)
MX (1) MX2023004831A (https=)
TW (1) TW202233666A (https=)
WO (1) WO2022090158A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード-ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP6214161B2 (ja) * 2009-12-21 2017-10-18 ジェネンテック, インコーポレイテッド 抗体製剤
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody

Similar Documents

Publication Publication Date Title
US11591406B2 (en) Treatment for multiple myeloma (MM)
JPWO2021183359A5 (https=)
JP2025183307A5 (https=)
JP2019532970A5 (https=)
AU2023375340A1 (en) Methods for the treatment of cardiovascular disease
JPWO2021224499A5 (https=)
JPWO2022053655A5 (https=)
JPWO2022090158A5 (https=)
US9486475B2 (en) PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JP7410256B2 (ja) 化膿性汗腺炎の治療のための汎elr+cxcケモカイン抗体
JPWO2019228514A5 (https=)
JPWO2021178779A5 (https=)
JPWO2023049694A5 (https=)
WO2026060205A1 (en) PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS
JPWO2023133388A5 (https=)
JPWO2022120137A5 (https=)
JPWO2021195362A5 (https=)
JPWO2022235758A5 (https=)
JPWO2023092062A5 (https=)
JPWO2022060955A5 (https=)
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease
JP2025084861A (ja) 再発型の多発性硬化症を治療するための方法
JPWO2022034044A5 (https=)
JPWO2023079485A5 (https=)